Sperimentazione in fase di reclutamento = ; Sperimentazione in corso = ; Sperimentazione conclusa = ; Finanziato da un ente associato a IRDiRC = ; Membro di una ERN =

Sperimentazioni cliniche nazionali

AUSTRIA

TIROL
INNSBRUCK

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS) -AT

Medizinische Universität Innsbruck

Universitätsklinik für Dermatologie, Venerologie und Allergologie

Ulteriori dettagli

FINLANDIA

Finland
HELSINKI

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS) -FI

HUS - Helsinki University Hospital

Department of Dermatology, Allergology and Venereology

Ulteriori dettagli

FRANCIA

ILE-DE-FRANCE
PARIS

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS) -FR

GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis

Service de dermatologie

Ulteriori dettagli

Sperimentazioni cliniche internazionali

FRANCIA

OCCITANIE
RAMONVILLE-SAINT-AGNE

Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study (Phase II) (coordination)

Orfagen

Ulteriori dettagli

SVEZIA

Region Stockholm
ADDRESS: NOT PROVIDED - SE

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS).

Institution: Information not provided - SE

Ulteriori dettagli